NCT/Study#
NCT06172296 /
COG-ANBL2131
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma
DISEASE GROUP:
Pediatric Oncology
current phase:
Phase III
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
